Death With Dignity Podcast

Episode 7 with Dr. Fred Millard

December 31, 2021 Andrew Flack Season 1 Episode 7
Death With Dignity Podcast
Episode 7 with Dr. Fred Millard
Show Notes

The team traveled to Moore's Cancer Center at UCSD to record this special episode.  Dr. Millard was a great source of information for all things cancer and you can learn more about him below.

Learn more about the podcast & follow our story - // @DWDPodcast2021 (Twitter)

About Frederick Millard, MD

Frederick Millard, MD, is a board-certified medical oncologist who specializes in treating people with genitourinary (urologic) cancers, including bladder cancer, kidney cancer, prostate cancer, testicular cancer and other germ cell tumors, as well as other rarer cancer types.

He is a founder and former co-director of the genitourinary oncology team at UC San Diego Health's Moores Cancer Center. His particular interest is in treatment of patients with germ cell tumors (testicular cancer) and improving the care of these patients in the San Diego community.

Dr. Millard also participates in the clinical research effort for patients with these illnesses, conducting clinical trials to help find new ways to improve treatments and the quality of life for people with urologic cancer. He is part of the only oncology clinical research program dedicated solely to urological cancers in the San Diego area.

As a professor in the Department of Medicine, Dr. Millard instructs medical students, residents, and fellows at UC San Diego School of Medicine. His work has appeared in many peer-reviewed publications, including Urologic Oncology, Clinical Cancer Research and the Clinical Genitourinary Cancer.

Dr. Millard completed a fellowship in hematology/oncology, and a residency in internal medicine at the Naval Medical Center in San Diego. He earned his medical degree from Sidney Kimmel Medical College in Philadelphia.

He is board certified in medical oncology, hematology and internal medicine, and is a member of the American Society of Clinical Oncology.